BioCentury | Jul 21, 2014
Company News

Novartis, ProBioGen deal

...ProBioGen granted Novartis a non-exclusive license to use ProBioGen’s GlymaxX technology to enhance antibody-dependent cell-mediated cytotoxicity...
...reduce dosing requirements. ProBioGen said financial terms are not disclosed. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland ProBioGen AG...
BioCentury | Mar 10, 2014
Company News

Merus, ProBioGen deal

...cytotoxicity (ADCC) activity on an undisclosed bispecific antibody in preclinical development to treat solid tumors. ProBioGen's...
...dosing requirements. The companies declined to disclose financial details. Merus B.V. , Utrecht, the Netherlands ProBioGen AG...
BioCentury | Oct 31, 2011
Company News

Inhibrx, ProBioGen deal

...Inhibrx received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC...
...GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC) activity for several undisclosed oncology antibodies. Additionally, ProBioGen...
...development and manufacturing services to help Inhibrx with process development for undisclosed recombinant therapeutic proteins. ProBioGen...
BioCentury | Aug 15, 2011
Company News

ProBioGen, Boehringer Ingelheim deal

...Boehringer received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC...
...jointly market the technology and offer it to customers royalty-free. Financial details were not disclosed. ProBioGen AG...
BioCentury | Jun 21, 2010
Company News

Minapharm, ProBioGen deal

...Minapharm acquired 95% of ProBioGen for €30.4 million ($36.8 million), including undisclosed earn-outs. ProBioGen is a...
...and coagulation disorders (see BioCentury, April 23, 2007). Wieland Wolf was hired as CEO of ProBioGen...
...Wafik Bardissi replaces Hubertus Leonhardt as chairman of ProBioGen. Minapharm Pharmaceuticals S.A.E. (Cairo:MIPH), Cairo, Egypt ProBioGen AG...
BioCentury | Jun 7, 2010
Company News

Affiris, ProBioGen deal

...Affiris will use ProBioGen's Human Artificial Lymph Node (HuALN) technology to assist in the selection of...
...structures to predict drug-related effects. Further details were not disclosed. Affiris AG , Vienna, Austria ProBioGen AG...
BioCentury | Apr 5, 2010
Company News

ProBioGen management update

ProBioGen AG , Berlin, Germany Business: Gene/Cell therapy Hired: Volker Sandig as CSO, formerly at the Merck Research Laboratories unit of Merck & Co. Inc. ; he replaces Uwe Marx, who departed for the Technical University...
BioCentury | Apr 14, 2008
Finance

Ebb & Flow

...and the SHS management team. SHS investments include antibody company Affimed and recombinant protein company ProBioGen...
BioCentury | Oct 15, 2007
Company News

ProBioGen management update

ProBioGen AG , Berlin, Germany Business: Gene/Cell therapy Hired: Gertraud Unterrainer as CFO, formerly CFO of Biovertis AG WIR Staff...
BioCentury | Sep 24, 2007
Company News

DBV management update

...principal at Apax Partners; Hing Kin Chan as CBO, formerly VP of commercial development at ProBioGen AG...
Items per page:
1 - 10 of 27
BioCentury | Jul 21, 2014
Company News

Novartis, ProBioGen deal

...ProBioGen granted Novartis a non-exclusive license to use ProBioGen’s GlymaxX technology to enhance antibody-dependent cell-mediated cytotoxicity...
...reduce dosing requirements. ProBioGen said financial terms are not disclosed. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland ProBioGen AG...
BioCentury | Mar 10, 2014
Company News

Merus, ProBioGen deal

...cytotoxicity (ADCC) activity on an undisclosed bispecific antibody in preclinical development to treat solid tumors. ProBioGen's...
...dosing requirements. The companies declined to disclose financial details. Merus B.V. , Utrecht, the Netherlands ProBioGen AG...
BioCentury | Oct 31, 2011
Company News

Inhibrx, ProBioGen deal

...Inhibrx received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC...
...GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC) activity for several undisclosed oncology antibodies. Additionally, ProBioGen...
...development and manufacturing services to help Inhibrx with process development for undisclosed recombinant therapeutic proteins. ProBioGen...
BioCentury | Aug 15, 2011
Company News

ProBioGen, Boehringer Ingelheim deal

...Boehringer received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC...
...jointly market the technology and offer it to customers royalty-free. Financial details were not disclosed. ProBioGen AG...
BioCentury | Jun 21, 2010
Company News

Minapharm, ProBioGen deal

...Minapharm acquired 95% of ProBioGen for €30.4 million ($36.8 million), including undisclosed earn-outs. ProBioGen is a...
...and coagulation disorders (see BioCentury, April 23, 2007). Wieland Wolf was hired as CEO of ProBioGen...
...Wafik Bardissi replaces Hubertus Leonhardt as chairman of ProBioGen. Minapharm Pharmaceuticals S.A.E. (Cairo:MIPH), Cairo, Egypt ProBioGen AG...
BioCentury | Jun 7, 2010
Company News

Affiris, ProBioGen deal

...Affiris will use ProBioGen's Human Artificial Lymph Node (HuALN) technology to assist in the selection of...
...structures to predict drug-related effects. Further details were not disclosed. Affiris AG , Vienna, Austria ProBioGen AG...
BioCentury | Apr 5, 2010
Company News

ProBioGen management update

ProBioGen AG , Berlin, Germany Business: Gene/Cell therapy Hired: Volker Sandig as CSO, formerly at the Merck Research Laboratories unit of Merck & Co. Inc. ; he replaces Uwe Marx, who departed for the Technical University...
BioCentury | Apr 14, 2008
Finance

Ebb & Flow

...and the SHS management team. SHS investments include antibody company Affimed and recombinant protein company ProBioGen...
BioCentury | Oct 15, 2007
Company News

ProBioGen management update

ProBioGen AG , Berlin, Germany Business: Gene/Cell therapy Hired: Gertraud Unterrainer as CFO, formerly CFO of Biovertis AG WIR Staff...
BioCentury | Sep 24, 2007
Company News

DBV management update

...principal at Apax Partners; Hing Kin Chan as CBO, formerly VP of commercial development at ProBioGen AG...
Items per page:
1 - 10 of 27